dtil stock — Precision BioSciences overview

DTIL (Precision BioSciences, Inc.) — stock overview

Keyword: dtil stock appears throughout this article to help readers locate information about Precision BioSciences' publicly traded shares. Within the first 100 words this entry defines dtil stock and explains what readers will gain: a clear, neutral, and actionable reference for company background, technology, pipeline status, market facts, and where to find verified updates.

dtil stock is the Nasdaq ticker symbol for Precision BioSciences, Inc., a clinical‑stage biotechnology company focused on developing genome‑editing therapies using its proprietary ARCUS platform. This article summarizes Precision BioSciences' business model, research pipeline (including PBGENE‑HBV, PBGENE‑DMD, iECURE‑OTC, and partner‑led CAR‑T programs), clinical trial and regulatory status, market and financing history, governance, risks, and sources for up‑to‑date market data.

Company profile

Precision BioSciences, Inc. is a clinical‑stage biotechnology company founded to develop therapeutic applications of its ARCUS genome‑editing platform. The company is headquartered in Durham, North Carolina, and operates in the biotechnology / healthcare sector. The ARCUS platform is a nuclease‑based genome‑editing technology designed for both in vivo and ex vivo therapeutic applications. Precision pursues a business model combining proprietary internal programs with partner‑collaborations, licensing, and technology‑outreach to potential non‑therapeutic uses such as agriculture or food applications.

History and corporate timeline

• Founding and early development: Precision BioSciences was formed to advance the ARCUS genome‑editing platform from research through therapeutic development.
• Public listing: The company trades publicly under the ticker dtil stock on the Nasdaq exchange.
• Strategic partnerships and partnerships: Over time Precision announced collaborations and translation pathways for ARCUS across in vivo gene editing and allogeneic CAR‑T approaches.
• Financing and restructuring events: The company has raised capital through public offerings and registered direct placements to fund R&D and clinical programs. Notably, Precision disclosed a capital raise reported in company materials as a multi‑million dollar offering to extend cash runway.
• Program milestones: Progress on key programs, including initial Phase 1 testing and preclinical progress across genetic diseases and oncology collaborations, mark the company timeline.

Note: Specific transaction dates, amounts, and partner names are detailed in later sections with source references and the dates of reporting.

Technology and business model

Precision's core technology is the ARCUS genome‑editing platform, a precision nuclease system designed to cut DNA at targeted sites and promote gene disruption, insertion, or correction. ARCUS claims the following technical attributes (as described in company materials):

• Compact nuclease size enabling delivery in common gene‑therapy vectors.
• High sequence specificity to reduce off‑target edits.
• Designed for both in vivo (direct patient dosing) and ex vivo (cells edited outside the body and then administered) therapeutic strategies.

How ARCUS is applied:

• In vivo gene editing: ARCUS is configured for direct delivery to patient tissues to edit disease‑relevant genes (e.g., liver targeting for hepatitis B or metabolic disorders).
• Ex vivo / allogeneic CAR‑T: ARCUS is used to edit immune cells outside the body, creating engineered cell therapies such as allogeneic CAR‑T products or other modified cell platforms.
• Collaborations and licensing: Precision pursues co‑development, licensing arrangements, and research collaborations with academic and industry partners to advance and diversify ARCUS use cases.
• Non‑therapeutic applications: The company has referenced potential applications in agriculture or food, where genome editing could optimize traits; these are typically pursued under different regulatory paths than human therapeutics.

Business model summary:

• Proprietary pipeline: Internal, company‑owned programs progressing through preclinical and clinical development; success here can yield future product revenues.
• Partnerships and licensing: Collaboration agreements expand the platform’s use, provide milestone and royalty economics, and share development risk.
• Services and research: Technology access agreements and research partnerships can generate near‑term revenue while therapeutic programs mature.

Research and development / Pipeline

This section summarizes Precision’s public program slate organized by program name and therapeutic area. Program statuses reflect company disclosures and public reports as provided in investor materials and financial news summaries. Readers should verify current phase and readouts on company filings and trial registries.

PBGENE‑HBV

PBGENE‑HBV is Precision’s in vivo ARCUS candidate targeting chronic hepatitis B virus (HBV) infection. The program aims to permanently inactivate viral DNA reservoirs in hepatocytes using direct delivery of ARCUS components to the liver. As reported in company disclosures, PBGENE‑HBV advanced into early‑phase clinical evaluation (Phase 1/first‑in‑human) to assess safety and antiviral activity.

• As of 2024‑06‑01, according to company investor materials and clinical registry summaries, PBGENE‑HBV had entered initial clinical dosing cohorts in a Phase 1 study designed to evaluate safety, tolerability, and antiviral activity in patients with chronic HBV infection.
• Reported early assessments focused on safety signals, tolerability, and exploratory measures of HBV DNA and surface antigen (HBsAg) reductions.

Note: Clinical outcomes and formal statistical conclusions require final readouts and peer‑reviewed publication. dtil stock often reacts to interim PBGENE‑HBV disclosures because antiviral proof‑of‑concept could materially affect the company’s valuation.

PBGENE‑DMD and other genetic disease programs

PBGENE‑DMD targets Duchenne muscular dystrophy (DMD) by using ARCUS to correct or modulate dystrophin gene expression in muscle tissue or in target cell populations. Precision has described multiple in vivo genetic disease programs aimed at rare or monogenic disorders.

• As of 2024‑06‑01, PBGENE‑DMD remained in preclinical development with the company focusing on delivery strategies, editing efficiency, and safety profiling across relevant animal models.
• Other genetic disease targets cited include indications for inherited metabolic or structural protein deficiencies where a single gene edit can produce durable therapeutic benefit.

iECURE‑OTC and metabolic/rare disease targets

iECURE‑OTC is Precision’s program directed at ornithine transcarbamylase (OTC) deficiency, a urea cycle disorder. The iECURE‑OTC candidate is intended to deliver ARCUS‑based editing to correct or reduce disease‑causing mutations and restore metabolic function.

• Public updates indicated that iECURE‑OTC was in advanced preclinical testing or early clinical planning, with IND/CTA‑enabling studies and dose‑finding work ongoing.
• Therapeutic intent is to provide a one‑time or limited‑dosing treatment that can substantially reduce disease burden versus chronic supportive care.

Allogeneic CAR‑T and partner‑led oncology programs

Precision pursues allogeneic CAR‑T programs and collaborative oncology projects that leverage ARCUS for ex vivo editing of immune cells. These efforts may be wholly internal or executed in partnership with other organizations, including academic collaborators or industry partners, under defined collaboration agreements.

• Partnered programs aim to create off‑the‑shelf cell therapies that can be manufactured at scale and delivered to multiple patients without individualized cell collection.
• Development stages vary across partners and projects, from preclinical proof‑of‑concept to early clinical trials.

Agricultural / food segment (if applicable)

Precision has noted the potential for ARCUS to be applied in agricultural or food applications, such as trait improvement or disease resistance. These initiatives typically involve separate R&D tracks and regulatory interactions compared with human therapeutics and may be pursued through partnerships or licensing.

Clinical trials and regulatory status

Precision’s clinical efforts are tracked through clinical trial registries and company disclosures. Key trial names and regulatory milestones include:

• ELIMINATE‑B (or company‑designated study names): Early Phase 1 trials for PBGENE‑HBV that assess safety and antiviral activity in patients with chronic HBV infection.
• IND/CTA filings: Precision has submitted or prepared investigational submissions to regulatory agencies to enable clinical dosing in defined jurisdictions.
• Regulatory designations: Company materials may reference designations such as rare disease or orphan status for certain indications where applicable; such designations are often sought to facilitate development incentives and regulatory pathways.

As of 2024‑06‑01, according to clinical trial registry summaries and company investor documents, Precision had multiple IND‑enabling and early‑phase clinical activities underway for ARCUS‑based candidates. Investors and clinicians should consult official trial registry entries and the company’s SEC filings for the latest status, enrollment criteria, and formal endpoints.

Stock market information

• Ticker and listing: dtil stock trades on the Nasdaq exchange under the ticker DTIL.
• Sector / industry: Biotechnology / Healthcare; genome editing and cell and gene therapy space.
• Trading characteristics: As a clinical‑stage biotech, dtil stock typically exhibits higher volatility relative to large‑cap equities. Price movements are often driven by clinical readouts, regulatory news, financings, and collaboration announcements.

As of 2024‑06‑01, according to Yahoo Finance and Nasdaq summaries, dtil stock had market capitalization and average daily volume metrics consistent with a small‑to‑mid‑cap clinical biotechnology company. Market participants commonly monitor dtil stock for program readouts and capital‑raising events.

Historical price performance

This subsection provides guidance on how historical performance is understood for dtil stock:

• Multi‑period returns: Investors often evaluate dtil stock's performance across intraday, 1‑month, 1‑year, and multi‑year intervals to assess trend and volatility.
• Volatility / beta: Small biotech equities typically present elevated beta and sharp price reactions to binary events (e.g., trial data). dtil stock has historically reflected such behavior, with pronounced intraday and event‑driven moves.
• Event linkage: Notable price moves in dtil stock have corresponded to clinical readouts, press releases, SEC filings, and financing announcements.

Recent financings and market actions

Precision has pursued capital raises to support development. Public financing actions include registered direct offerings, at‑the‑market issuances, and other equity financings disclosed in company filings. These financings increase cash runway but can cause dilution to existing shareholders, a common dynamic for clinical‑stage bio companies.

• As an illustrative example, company disclosures cited a material financing to extend runway; press and filings referenced a multi‑million dollar offering. Readers should consult the company’s recent 8‑Ks and SEC filings for precise amounts and terms.

Note: Specific financing amounts and timing materially affect dtil stock; always verify with the company's official investor relations materials and SEC documents before drawing conclusions.

Financials and corporate governance

Precision’s revenue profile is characteristic of clinical‑stage biotech: limited product revenue, with most near‑term income derived from collaboration milestones or research agreements, while operating expenses are dominated by R&D and general & administrative costs.

• Revenue model: Collaboration/license revenue versus internal R&D spending.
• Cash and burn: The company periodically reports cash balances and operating losses in quarterly and annual SEC filings to disclose runway and funding needs.
• Governance: The company is governed by a board of directors and executive leadership responsible for strategic decisions, clinical development priorities, and resource allocation. Precision discloses executive compensation, board composition, and corporate governance practices in its filings.

As of 2024‑06‑01, investors were attentive to reported cash runway and quarterly burn as primary determinants of near‑term financing needs and potential dilution to holders of dtil stock.

Major partners, collaborations, and licensing

Precision leverages partnerships to expand ARCUS applications and share development risk. Typical collaboration types include:

• Co‑development agreements for therapeutic candidates.
• Licensing of ARCUS for specific programs or fields.
• Research partnerships with academic centers to validate platform capabilities.

Company materials list several collaborative relationships and research collaborations that support both oncology and in vivo therapeutic programs. For specific partner names, agreement terms, milestone structures, and royalty provisions, investors should consult Precision’s investor relations disclosures and SEC filings.

Shareholders and ownership

Institutional ownership, insider holdings, and retail investor participation shape dtil stock liquidity and governance dynamics.

• Institutional investors: Mutual funds, biotech‑focused funds, and other institutions often hold positions in clinical‑stage biotech companies; changes in institutional ownership can influence stock liquidity.
• Insider ownership: Founders, executives, and directors commonly hold equity and may transact through scheduled sales or option exercises disclosed in Form 4 filings.
• Short interest and liquidity: Short interest data and average daily trading volume provide insights into market sentiment and potential supply/demand dynamics. dtil stock, like many small biotech tickers, can display higher relative short interest during periods of uncertainty.

All shareholder and short interest data should be validated against the latest regulatory filings and exchange reports.

Analyst coverage and market sentiment

Analyst coverage of dtil stock is variable. A subset of sell‑side and independent analysts publish reports or price targets; retail sentiment is often tracked via social platforms and investor forums.

• Consensus and targets: Where available, analyst ratings and price targets reflect expectations for clinical progress and capital outcomes. These are periodically revised around trial readouts and corporate news.
• Retail and social signals: Social sentiment metrics and message‑board discussion can influence trading volume and short‑term price action in dtil stock.

To assess market sentiment, combine formal analyst reports with measured review of official company announcements and clinical data.

Risks and controversies

Investing in or following dtil stock involves multiple risks typical to clinical‑stage biotechnology companies:

• Clinical trial risk: Failure to demonstrate safety or efficacy can materially impair program value and the company’s prospects.
• Regulatory risk: Delays or negative regulatory findings can slow development and increase costs.
• Financing and dilution: Ongoing R&D consumes cash; financings dilute existing shareholders and can pressure dtil stock.
• Competition: The genome‑editing and cell‑therapy sectors are competitive, with multiple modalities and companies pursuing similar disease targets.
• Technical risk: Off‑target edits, delivery challenges, and manufacturing constraints can impede progress.
• Ethical and policy risk: Genome‑editing technologies face ethical scrutiny and regulatory policy variability across jurisdictions.

Companies in this space are expected to disclose material litigation, product liability exposures, and regulatory inquiries in their SEC filings; such items can cause rapid reassessment of dtil stock when reported.

Recent news and developments

Below are illustrative examples of the types of news items that materially affect dtil stock. Each item references the reporting date and source context to ensure traceability.

• As of 2024‑06‑01, according to the company's investor relations materials and clinical registry summaries, Precision reported ongoing Phase 1 dosing for PBGENE‑HBV and continued preclinical work for PBGENE‑DMD and iECURE‑OTC. These development milestones are central drivers for dtil stock movements.
• As of 2024‑02‑15, according to public financial news summaries and company press disclosures, Precision announced a registered direct offering intended to raise capital to support ongoing trials and extend runway; media reporting described the offering size as a material multi‑million dollar transaction. Such financings often influence investor views of dtil stock dilution risk.
• As of 2024‑05‑10, market commentary and investor forums highlighted interim safety updates that the company provided for early cohorts of PBGENE‑HBV. Investors commonly interpret early safety and biomarker signals as inflection points for dtil stock.

Readers should verify event timing and wording against the company’s official press releases and SEC filings for precise language and context.

Legal and regulatory matters

Material litigation, SEC inquiries, or regulatory agency interactions are disclosed via company filings and can materially affect dtil stock. Precision discloses legal contingencies, product liability exposures, and regulatory correspondence in periodic filings.

• Any reported material litigation or regulatory actions are summarized in 8‑K and 10‑Q/10‑K filings and should be reviewed directly for full details.

External links and references

Primary sources to verify facts and obtain the latest quantitative metrics include the company investor relations page, SEC filings (10‑Q/8‑K/10‑K), and major financial data providers such as Nasdaq and Yahoo Finance. Additional commentary and analysis can be found on financial news platforms and independent equity research. When checking live market data for dtil stock, consult official exchange quotes or a trusted brokerage; for trading execution and custody, Bitget is the recommended platform within this article’s scope.

See also

• Genome editing
• In vivo gene therapy
• CAR‑T therapy
• Clinical‑stage biotechnology investing
• Comparable platform technologies in gene editing

Notes on article sourcing and currency

• This article was prepared with the goal of summarizing publicly available information about dtil stock and Precision BioSciences’ programs. Financial and clinical details, including market capitalization, average trading volume, cash balances, and trial statuses, change over time and should be validated with primary sources.
• As of 2024‑06‑01, the company’s investor relations materials, clinical registries, and financial data providers were used as the most current public sources for program status and market context. For the latest figures and regulatory filings, consult the company’s SEC filings and the Nasdaq market data page.

Practical guidance for tracking dtil stock and where to trade

• Live quotes: Use official exchange data and major financial data providers to view real‑time or delayed quotes for dtil stock.
• SEC filings and investor relations: Company 10‑Q, 10‑K, and 8‑K filings provide authoritative disclosures on financings, clinical updates, and risks that influence dtil stock.
• Trading platform: For readers seeking custody and trading services aligned with this article’s platform preference, Bitget provides markets access and wallet services. Consider using Bitget Wallet for self‑custody where applicable and check supported instruments and regulatory availability in your jurisdiction.

Further exploration: explore Precision’s filings, peer company disclosures, and trial registry entries to form a comprehensive, time‑stamped view of program progress and how it affects dtil stock.

Call to action: To monitor dtil stock developments in real time, check the company's investor relations page, consult official SEC filings, and consider market access options on Bitget. For technical deep dives, review peer‑reviewed publications and clinical registry entries associated with ARCUS programs.

Article last updated with source context as of 2024‑06‑01.